Partnering for global health

> Imagine a world where no one dies of a vaccine-preventable disease

Sanofi Pasteur is interested in partners who will share our pursuit of innovation and our drive for excellence, while becoming a part of our market success story. We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases.

Sanofi Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. Our collaborations cover virtually all aspects of vaccine development, including early-stage research.

Examples of current partnerships and technology investments include: vaccines for dengue fever, Japanese encephalitis, S. pneumoniae, N. meningitidis B, and M. tuberculosis; pediatric combination vaccines; rabies monoclonal antibodies; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.

When partnering with sanofi pasteur, you will interact with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed succesfully and nurtured for the mutual benefit of all parties.

This approach utilizes the value-added sanofi pasteur alliance management capability, which focuses on the relationship by facilitating open communication trust, understanding and clear expectations across the project lifespan. Combined with the technical competency of the alliance, this balance provides a wellrounded environment for your technology to flourish.

Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:

Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases

- Novel antigens and methods for antigen discovery and characterization
- Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies
- New ways to administer vaccines
- Vaccine vectors suitable for nasal or oral use

Agents to enhance vaccine immune responses

- Adjuvants and immunomodulators
- Vaccine vectors and delivery systems intended to enhance or modify immune responses
- Biological and immunological studies to further characterize adjuvants and immunomodulators

Characterization and assay of immune responses and disease markers

- Animal models of human diseases
- In vitro models of human tissues, including the immune system
- Biological markers for evaluating the efficacy of prophylactic or therapeutic interventions
- Epidemiological studies relevant to the use of vaccines and immunotherapeutics

Tools for improving vaccine and monoclonal antibody research, development and production

- Development and application of new technologies in the areas of genomics and proteomics
- Prokaryotic or eukaryotic cell lines for antigen production
- Fermentor and bioreactor technology
- Disposable systems
- Online testing
- Downstream processing, purification and aseptic filling processes
- Process automation
- Preservatives and stabilizers
- Bioinformatics techniques for modeling, data handling and analysis
- Anti-counterfeiting technology

Please contact:

Jeffrey Almond, PhD
Vice President, Discovery and External Research and Development
Phone +33 4 3737 9453
jeffrey.almond@sanofipasteur.com

Jean-Marc Renard, MS, MBA
Vice President, Corporate Development
Phone +33 4 3737 3480
jean-marc.renard@sanofipasteur.com

or visit our website: **www.sanofipasteur.com**

sanofi pasteur
The vaccines division of sanofi-aventis Group